Avant Diagnostics, Inc.’s ("AVANT" or AVDX) technology intends to realize patient-focused precision medicine in cancer treatment.  Both biopharma companies developing drugs and oncologists treating patients find that Avant’s Theralink® assay has the potential to enable clear decision making for an individual patient’s cancer treatment using predictive biomarkers.

Tumor Biomarker Profiling: Driving Innovation in Personalized Medicine

At Avant Diagnostics, our approach is based on more than 16 years of research and development.  Our research indicates that genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions.  Our phosphoproteomic approach is the only platform that quantifies the activation state (phosphorylation) of drug target proteins and their downstream signaling partners within the tumor tissue.  Our advanced technology exploits our understanding of drug-receptor and drug-protein interactions that drive treatment responses.  The Theralink assay is being developed to provide physicians with a treatment decision support tool that could assist selecting therapies that are more likely to results in responses to treatment.  Our large panel of new predictive biomarkers is targeting therapeutic molecular inhibitors including some currently FDA approved therapies and certain investigational therapies, making Theralink® an invaluable tool for oncologists and biopharma clinical trials.

Enabling Early and Late Stage Drug Development for Biotechnology and Pharmaceutical Companies

Avant Diagnostics’ biopharma services business will help drug companies accelerate their drug discovery programs and facilitate development of companion diagnostics (CDx).  Avant’s technologies can be used to:

  • Stratify patients entering clinical trials (reduces trial costs by up to 50% with smaller cohorts);
  • Monitor on and off target drug effects;
  • Quantify the phosphoproteome within tumors to identify activation of resistance or compensatory pathways post-treatment;
  • Evaluate potential proteomic biomarkers for combination therapies; and
  • Potentially repurpose existing therapies for new indications (off-patent drugs and market expansion).

Providing Physicians with a Unique and Powerful Treatment Decision Information Resource

Avant provides personalized medicine data through its Theralink® assays, initially for breast cancer, to assist the treating physician in a data-driven process for treatment decision support and enable predictive biomarker-based patient selection.  Avant is the leading developer of phosphoproteomic technologies for measuring the activation state of key drug targets and signaling pathways, with applications across multiple cancer types, including breast, non-small cell lung, colorectal and pancreatic. Theralink® was developed to empower physicians with potentially actionable information to help them make time sensitive treatment decisions for their patients.  Theralink® was designed to provide new predictive biomarkers through the direct measurement of drug target activation mapping, making Theralink® instrumental in the development of companion diagnostics for molecular targeted therapies.  The information gathered through measurement of developed biomarkers has the potential to help physicians make molecularly rationalized treatment decisions that could improve treatment outcomes and reduce side effects by foregoing ineffective therapy.

Science Backed by Strong Leadership

Meet the team that is the driving force behind our success.

View Management Team »